Department of Urology, Urological Research Institute, University Vita-Salute San Raffaele, Milan, Italy.
Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060. Epub 2011 Aug 3.
The management of patients with clinical recurrence of prostate cancer after radical prostatectomy (RP) remains challenging.
To determine whether the removal of positive lymph nodes at [11C]choline positron emission tomography/computed tomography (PET/CT) scan may have an impact on the prognosis of patients with biochemical recurrence (BCR) and nodal recurrence after RP.
DESIGN, SETTING, AND PARTICIPANTS: Prospective analysis of 72 patients affected by BCR after RP associated with a nodal pathologic [11C]choline PET/CT scan.
Patients underwent salvage lymph node dissection (LND).
Biochemical response (BR) to treatment was defined as prostate-specific antigen (PSA) <0.2 ng/ml at 40 d after salvage LND. Kaplan-Meier and Cox regression analyses addressed time to and predictors of clinical recurrence (CR) after salvage LND, respectively.
Overall, 56.9% of patients achieved BR. Mean and median follow-up after LND were 39.4 and 39.8 mo, respectively. The 5-yr BCR-free survival rate was 19%. Preoperative PSA <4 ng/ml (hazard ratio [HR]: 0.12; p = 0.005), time to BCR <24 mo (HR: 7.52; p = 0.005), and negative lymph nodes at previous RP (HR: 0.19; p=0.04) represented independent predictors of BR. Overall, 5-yr CR-free and cancer-specific survival were 34% and 75%, respectively. At multivariable analyses, only PSA >4 ng/ml (HR: 2.13; p=0.03) and the presence of retroperitoneal uptake at PET/CT scan (HR=2.92; p=0.004) represented independent preoperative predictors of CR. Similarly, the presence of pathologic nodes in the retroperitoneum (HR: 2.78; p=0.02), higher number of positive lymph nodes (HR: 1.04; p=0.006), and complete BR to salvage LND (HR: 0.31; p=0.002) represented postoperative independent predictors of CR. Main limitations consisted of the lack of a control group and the heterogeneity of patients included in the analyses.
Salvage LND is feasible in patients with BCR after RP and nodal pathologic uptake at [11C]choline PET/CT scan. Biochemical response after surgery can be achieved in a consistent proportion of patients. Although most patients invariably progressed to BCR after surgery at longer follow-up, 35% of patients showed the absence of CR at 5 yr.
根治性前列腺切除术(RP)后前列腺癌临床复发患者的治疗仍具有挑战性。
确定在 [11C]胆碱正电子发射断层扫描/计算机断层扫描(PET/CT)扫描中阳性淋巴结的清除是否会影响 RP 后生化复发(BCR)和淋巴结复发患者的预后。
设计、地点和参与者:对 72 例因 RP 后出现生化复发并伴有淋巴结病理 [11C]胆碱 PET/CT 扫描的患者进行前瞻性分析。
患者接受挽救性淋巴结清扫术(LND)。
以 LND 后 40 d 时前列腺特异性抗原(PSA)<0.2 ng/ml 定义生化反应(BR)。Kaplan-Meier 和 Cox 回归分析分别探讨了挽救性 LND 后临床复发(CR)的时间和预测因素。
总体而言,56.9%的患者达到 BR。LND 后平均和中位随访时间分别为 39.4 和 39.8 个月。5 年 BCR 无复发生存率为 19%。术前 PSA<4ng/ml(风险比[HR]:0.12;p=0.005)、BCR<24mo(HR:7.52;p=0.005)和 RP 前淋巴结阴性(HR:0.19;p=0.04)是 BR 的独立预测因素。总体而言,5 年 CR 无复发生存率和癌症特异性生存率分别为 34%和 75%。多变量分析仅显示 PSA>4ng/ml(HR:2.13;p=0.03)和 PET/CT 扫描中存在腹膜后摄取(HR=2.92;p=0.004)是 CR 的独立术前预测因素。同样,腹膜后存在病理性淋巴结(HR:2.78;p=0.02)、阳性淋巴结数量较多(HR:1.04;p=0.006)和挽救性 LND 完全 BR(HR:0.31;p=0.002)是 CR 的术后独立预测因素。主要局限性在于缺乏对照组和分析中患者的异质性。
RP 后生化复发且 [11C]胆碱 PET/CT 扫描有淋巴结摄取的患者可行挽救性 LND。手术后可以使相当比例的患者达到生化缓解。尽管大多数患者在更长的随访中最终仍出现生化复发,但 5 年时仍有 35%的患者未出现 CR。